查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2082028

癌症免疫療法市場：2026-2032年全球市場預測（依療法、作用機制、治療階段、給藥途徑、適應症和最終用戶分類）

Cancer Immunotherapy Market by Therapy Type, Mechanism Of Action, Line Of Therapy, Route Of Administration, Indication, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 191 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，癌症免疫療法市場將成長至 2,447.2 億美元，複合年成長率為 7.52%。

主要市場統計數據
基準年 2025 1472.5億美元
預計年份：2026年 1578.1億美元
預測年份：2032年 2447.2億美元
複合年成長率 (%) 7.52%

癌症免疫療法執行摘要

癌症免疫療法已從一種專門的腫瘤治療方法轉變為癌症治療的核心支柱，重新定義了骨髓惡性腫瘤和固體癌的治療標準。免疫查核點抑制劑、CAR-T細胞療法、雙特異性抗體、抗體藥物偶聯物（ADC）聯合治療、治療性癌症疫苗、溶瘤病毒、細胞激素療法和腫瘤浸潤淋巴細胞療法，如今已成為臨床和商業策略的核心。

免疫療法領域的變革性變化

癌症免疫療法的格局正在發生變革，其驅動力在於從單一療法轉向合理的聯合治療、早期治療以及基於生物標記的患者群體選擇。儘管PD-1、PD-L1和CTLA-4抑制劑已將免疫腫瘤學確立為主流治療領域，但下一代療法正致力於解決抗藥性、復發以及腫瘤微環境抑制等問題。

人工智慧（AI）的累積影響

從藥物發現和開發到商業化，人工智慧正在癌症免疫療法的各個階段創造累積價值。人工智慧驅動的標靶發現、抗原預測、新抗原優先排序、空間生物學分析、數位病理學和多模態生物標記建模，正在幫助研究人員識別最有可能對治療產生反應的患者，並設計更精準的治療策略。

關鍵區域洞察

北美憑藉其密集的臨床實驗室網路、先進的學術癌症中心、完善的FDA監管管道以及強大的生物製藥資金籌措環境，仍然是全球癌症免疫療法創新中心。美國在查核點抑制劑、細胞療法、雙特異性抗體和生物標記檢測的早期應用方面處於領先地位，而加拿大則透過其公共醫療保健系統、腫瘤研究網路以及以循證醫學報銷審查為支撐的精準醫療計劃做出貢獻。

關鍵群體特定見解

七國集團憑藉著成熟的監管體系、高密度的臨床實驗室、專業的癌症中心和完善的醫療保險報銷管道，持續推動免疫腫瘤領域的尖端創新，使其成為查核點抑制劑、細胞療法、雙特異性抗體和伴隨診斷的關鍵市場。北約成員國的市場與許多先進的腫瘤治療體系重疊，凸顯了安全可靠的藥品供應鏈、資料保護、網路安全防護完善的臨床基礎設施以及強大的生技藥品生產能力的重要性。

主要國家概況

美國憑藉FDA的批准、先進的生物標記檢測、廣泛的臨床檢測管道、學術癌症網路以及對生命科學領域的大力資金籌措，引領著癌症免疫療法的商業化進程。加拿大則強調以實證醫學為基礎的療法應用，並透過省級醫保報銷機制和全國性的癌症評估流程來實現這一目標。墨西哥和巴西是拉丁美洲重要的准入市場，它們的進展取決於公私合營在癌症治療、特藥分銷、臨床研究參與以及診斷技術推廣等方面的合作。

為行業領導者提供的實用建議

產業領導者應優先考慮以生物標記主導的研發、基於明確作用機制的聯合治療策略，以及能夠證明在特定患者群體中具有持續療效的臨床試驗設計。為了提高臨床效用、獲得監管機構的信任和支付方的認可，周密的伴隨診斷規劃、全面的患者招募、分散的臨床試驗能力以及真實世界數據（RWE）的生成至關重要。

調查方法

本執行摘要基於二手研究方法，利用公開可靠的來源，包括世界衛生組織的癌症流行病學數據、主要監管機構的監管資訊來源、臨床實驗室註冊資訊、同行評審的腫瘤學文獻、醫療技術評估研究途徑、腫瘤學指南的更新以及免疫腫瘤學發展活動。

結論

癌症免疫療法正進入一個更複雜且以價值主導的階段，其特點是精準的生物標記、先進的生技藥品、基因改造細胞療法、人工智慧驅動的藥物研發以及區域間醫療資源分配不均。全球癌症發生率的上升以及骨髓惡性腫瘤和固體癌治療的持續進展，為該領域的長期成長提供了支撐。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 工業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章 癌症免疫療法市場：依治療方法分類

  • 癌症疫苗
  • CAR-T療法
  • CTLA-4抑制劑
  • 溶瘤病毒療法
  • PD-1抑制劑
  • PD-L1抑制劑

第8章：癌症免疫療法市場：依作用機制分類

  • 過繼性細胞移植
  • 查核點抑制劑
  • 細胞激素療法
  • 溶瘤病毒療法
  • 疫苗療法

第9章：癌症免疫療法市場：依治療階段分類

  • 第 1 行
  • 從第四行開始
  • 第二行
  • 第三行

第10章：癌症免疫療法市場：依給藥途徑分類

  • 腫瘤內部
  • 靜脈
  • 皮下

第11章：癌症免疫療法市場：依適應症分類

  • 骨髓惡性腫瘤
    • 白血病
    • 淋巴瘤
    • 多發性骨髓瘤
  • 固體癌
    • 乳癌
    • 結腸癌
    • 肺癌
    • 黑色素瘤

第12章 癌症免疫療法市場：依最終用戶分類

  • 醫院
  • 研究機構
  • 專科診所

第13章 癌症免疫療法市場：按地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第14章 癌症免疫療法市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 癌症免疫療法市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第17章：公司簡介

  • Adaptimmune Therapeutics
  • Amgen Inc.
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Bayer AG
  • BeiGene, Ltd.
  • BioNTech SE
  • Boehringer Ingelheim
  • Bristol-Myers Squibb Company
  • Cellectis SA
  • Daiichi Sankyo Company, Limited
  • Eli Lilly and Company
  • Fate Therapeutics, Inc.
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • Immunocore Holdings PLC
  • Iovance BIoTherapeutics, Inc.
  • Johnson & Johnson
  • Merck & Co.
  • Moderna, Inc.
  • Novartis AG
  • Pfizer Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Roche Holding AG
  • Sanofi
  • Takeda Pharmaceutical Company
Product Code: MRR-4330CC794A6B

The Cancer Immunotherapy Market is projected to grow by USD 244.72 billion at a CAGR of 7.52% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 147.25 billion
Estimated Year [2026] USD 157.81 billion
Forecast Year [2032] USD 244.72 billion
CAGR (%) 7.52%

Cancer Immunotherapy Executive Summary

Cancer immunotherapy has moved from a specialized oncology approach to a core pillar of cancer treatment, reshaping standards of care across hematologic malignancies and solid tumors. Immune checkpoint inhibitors, CAR-T cell therapies, bispecific antibodies, antibody-drug conjugate combinations, therapeutic cancer vaccines, oncolytic viruses, cytokine-based therapies, and tumor-infiltrating lymphocyte therapies are now central to clinical and commercial strategies.

The growth imperative is supported by verified epidemiology. The International Agency for Research on Cancer reported approximately 20 million new cancer cases and 9.7 million cancer deaths worldwide in 2022 and projects more than 35 million new cancer cases by 2050. This rising burden is accelerating demand for durable, biomarker-guided, and combination-based immuno-oncology treatments that can improve survival while supporting precision medicine adoption.

Transformative Shifts in the Immunotherapy Landscape

The cancer immunotherapy landscape is being transformed by a shift from single-agent therapies toward rational combinations, earlier-line treatment, and biomarker-selected patient populations. PD-1, PD-L1, and CTLA-4 inhibitors established immuno-oncology as a mainstream treatment category, while next-generation modalities are addressing resistance, relapse, and tumor microenvironment suppression.

Manufacturing and delivery models are also changing. Autologous cell therapy capacity, allogeneic platforms, decentralized manufacturing, vein-to-vein logistics, and real-world evidence programs are becoming competitive differentiators. At the same time, payers and health technology assessment agencies are applying stricter scrutiny to durability, quality-adjusted survival, safety management, and total cost of care.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is creating cumulative value across cancer immunotherapy discovery, development, and commercialization. AI-enabled target discovery, antigen prediction, neoantigen prioritization, spatial biology analysis, digital pathology, and multimodal biomarker modeling are helping researchers identify patients most likely to respond and design more precise treatment strategies.

In clinical operations, AI supports trial matching, eligibility screening, site selection, adverse event signal detection, and real-world evidence generation. The most immediate value is not replacing clinical judgment but improving decision speed, reducing failed enrollment, and strengthening companion diagnostic strategies. Leaders that combine AI governance, high-quality datasets, and regulatory-grade validation are positioned to accelerate immuno-oncology innovation responsibly.

Key Regional Insights

North America remains a global center for cancer immunotherapy innovation due to dense clinical trial networks, advanced academic cancer centers, FDA regulatory pathways, and strong biopharma financing. The United States anchors early adoption of checkpoint inhibitors, cell therapies, bispecific antibodies, and biomarker testing, while Canada contributes through public health systems, oncology research networks, and precision medicine initiatives supported by evidence-based reimbursement review.

Europe is shaped by EMA oversight, national reimbursement systems, and health technology assessment requirements that prioritize evidence quality, cost-effectiveness, and real-world outcomes. Asia-Pacific is expanding as China, Japan, South Korea, India, and Australia increase clinical research output, biologics manufacturing, regulatory modernization, and oncology infrastructure. Latin America, led by Brazil and Mexico, is improving specialty access and clinical trial participation but continues to face affordability, pathology, and molecular diagnostic capacity constraints. The Middle East, particularly GCC markets, is investing in tertiary cancer centers, genomic medicine, and specialty procurement, while Africa's opportunity depends on strengthening pathology, cold-chain logistics, oncology workforce capacity, pharmacovigilance, and equitable access programs.

Key Group Insights

The G7 continues to drive premium immuno-oncology innovation through mature regulatory systems, high clinical trial density, specialized cancer centers, and established reimbursement pathways, making it a critical launch environment for checkpoint inhibitors, cell therapies, bispecific antibodies, and companion diagnostics. NATO markets overlap with many advanced oncology systems and also highlight the importance of secure pharmaceutical supply chains, data protection, cyber-resilient clinical infrastructure, and resilient biologics manufacturing.

The European Union benefits from centralized EMA authorization and a growing emphasis on joint health technology assessment, which can improve market consistency while maintaining pressure on comparative effectiveness and value demonstration. BRICS countries offer population scale, expanding clinical research participation, increasing domestic biologics capacity, and rising demand for oncology access, though availability varies significantly by reimbursement, diagnostics, and infrastructure. ASEAN markets are advancing unevenly, with Singapore, Thailand, and Malaysia showing stronger specialty oncology capabilities, while broader regional adoption depends on workforce development, pathology access, and affordability. GCC countries are using national transformation agendas to expand precision oncology, specialty procurement, genomic medicine, and regional cancer care hubs.

Key Country Insights

The United States leads cancer immunotherapy commercialization through FDA approvals, advanced biomarker testing, broad clinical trial access, academic cancer networks, and strong life sciences financing. Canada emphasizes evidence-based adoption through provincial reimbursement systems and pan-Canadian oncology assessment processes. Mexico and Brazil represent important Latin American access markets, with progress tied to public-private oncology capacity, specialty distribution, clinical research participation, and diagnostic expansion.

In Europe, the United Kingdom combines NHS real-world evidence capabilities with strong oncology research, while Germany and France are central to reimbursement evaluation, clinical adoption, and biomarker testing infrastructure. Italy and Spain contribute robust oncology networks and expanding access to precision medicine, while Russia maintains domestic oncology demand despite geopolitical, regulatory, and supply access complexity. In Asia-Pacific, China has become a major immuno-oncology development engine supported by large clinical trial activity and domestic biologics capacity; India offers large patient populations, expanding biosimilar capabilities, and rising oncology infrastructure; Japan supports high-quality regulatory and clinical infrastructure with strong adoption of innovative oncology therapies; South Korea is strong in biologics, digital health, and cell therapy innovation; and Australia remains a preferred clinical trial destination with globally respected cancer centers and strong translational research capabilities.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize biomarker-led development, combination strategies with clear mechanistic rationale, and trial designs that demonstrate durable benefit in defined patient segments. Strong companion diagnostic planning, inclusive enrollment, decentralized trial capabilities, and real-world evidence generation are essential to improve clinical utility, regulatory confidence, and payer acceptance.

Manufacturers should strengthen cell and gene therapy supply chains, invest in scalable manufacturing, and build capabilities for adverse event management, including cytokine release syndrome and immune-related toxicities. Commercial teams should prepare access dossiers that address survival, quality of life, durability, site-of-care economics, and long-term value. Partnerships with academic centers, diagnostic developers, AI platforms, contract manufacturers, and regional health systems can accelerate access, operational resilience, and differentiation.

Research Methodology

The executive summary is developed using a secondary research approach grounded in publicly available and authoritative sources, including cancer epidemiology from international health agencies, regulatory information from major agencies, clinical trial registries, peer-reviewed oncology literature, health technology assessment practices, oncology guideline updates, and immuno-oncology development activity.

The methodology emphasizes triangulation across epidemiological data, therapeutic approvals, clinical development patterns, regional healthcare infrastructure, reimbursement dynamics, manufacturing considerations, diagnostics adoption, and technology signals. Insights are synthesized to support strategic decision-making for executives, investors, manufacturers, diagnostics developers, healthcare providers, and policy stakeholders operating across the cancer immunotherapy value chain.

Conclusion

Cancer immunotherapy is entering a more complex and value-driven phase defined by precision biomarkers, advanced biologics, engineered cell therapies, AI-enabled discovery, and regional access differentiation. The sector's long-term opportunity is supported by rising global cancer incidence and continued clinical progress across both hematologic malignancies and solid tumors.

Sustainable leadership will depend on evidence generation, scalable manufacturing, equitable access, diagnostic readiness, and disciplined access strategies. Organizations that align innovation with measurable patient outcomes, safety management, real-world value, and payer expectations will be best positioned to compete in the evolving global cancer immunotherapy landscape.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Cancer Immunotherapy Market, by Therapy Type

  • 7.1. Cancer Vaccines
  • 7.2. CAR-T Therapy
  • 7.3. CTLA-4 Inhibitors
  • 7.4. Oncolytic Virus Therapy
  • 7.5. PD-1 Inhibitors
  • 7.6. PD-L1 Inhibitors

8. Cancer Immunotherapy Market, by Mechanism Of Action

  • 8.1. Adoptive Cell Transfer
  • 8.2. Checkpoint Inhibitors
  • 8.3. Cytokine Therapy
  • 8.4. Oncolytic Virus Therapy
  • 8.5. Vaccine Therapy

9. Cancer Immunotherapy Market, by Line Of Therapy

  • 9.1. First Line
  • 9.2. Fourth Line And Beyond
  • 9.3. Second Line
  • 9.4. Third Line

10. Cancer Immunotherapy Market, by Route Of Administration

  • 10.1. Intratumoral
  • 10.2. Intravenous
  • 10.3. Subcutaneous

11. Cancer Immunotherapy Market, by Indication

  • 11.1. Hematologic Malignancies
    • 11.1.1. Leukemia
    • 11.1.2. Lymphoma
    • 11.1.3. Multiple Myeloma
  • 11.2. Solid Tumors
    • 11.2.1. Breast Cancer
    • 11.2.2. Colorectal Cancer
    • 11.2.3. Lung Cancer
    • 11.2.4. Melanoma

12. Cancer Immunotherapy Market, by End User

  • 12.1. Hospitals
  • 12.2. Research Institutes
  • 12.3. Specialty Clinics

13. Cancer Immunotherapy Market, by Region

  • 13.1. Asia-Pacific
  • 13.2. North America
  • 13.3. Latin America
  • 13.4. Europe
  • 13.5. Middle East
  • 13.6. Africa

14. Cancer Immunotherapy Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Cancer Immunotherapy Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Concentration Analysis, 2025
    • 16.1.1. Concentration Ratio (CR)
    • 16.1.2. Herfindahl Hirschman Index (HHI)
  • 16.2. Recent Developments & Impact Analysis, 2025
  • 16.3. Product Portfolio Analysis, 2025
  • 16.4. Benchmarking Analysis, 2025

17. Company Profiles

  • 17.1. Adaptimmune Therapeutics
  • 17.2. Amgen Inc.
  • 17.3. Astellas Pharma Inc.
  • 17.4. AstraZeneca PLC
  • 17.5. Bayer AG
  • 17.6. BeiGene, Ltd.
  • 17.7. BioNTech SE
  • 17.8. Boehringer Ingelheim
  • 17.9. Bristol-Myers Squibb Company
  • 17.10. Cellectis S.A.
  • 17.11. Daiichi Sankyo Company, Limited
  • 17.12. Eli Lilly and Company
  • 17.13. Fate Therapeutics, Inc.
  • 17.14. Gilead Sciences, Inc.
  • 17.15. GlaxoSmithKline plc
  • 17.16. Immunocore Holdings PLC
  • 17.17. Iovance Biotherapeutics, Inc.
  • 17.18. Johnson & Johnson
  • 17.19. Merck & Co.
  • 17.20. Moderna, Inc.
  • 17.21. Novartis AG
  • 17.22. Pfizer Inc.
  • 17.23. Regeneron Pharmaceuticals, Inc.
  • 17.24. Roche Holding AG
  • 17.25. Sanofi
  • 17.26. Takeda Pharmaceutical Company

LIST OF FIGURES

  • FIGURE 1. GLOBAL CANCER IMMUNOTHERAPY MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL CANCER IMMUNOTHERAPY MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL CANCER IMMUNOTHERAPY MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL CANCER IMMUNOTHERAPY MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL CANCER IMMUNOTHERAPY MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 7. GLOBAL CANCER IMMUNOTHERAPY MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 8. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY LINE OF THERAPY, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY LINE OF THERAPY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY END USER, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 23. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 24. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 25. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL CANCER VACCINES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL CANCER VACCINES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL CANCER VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL CAR-T THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL CAR-T THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL CAR-T THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL CTLA-4 INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL CTLA-4 INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL CTLA-4 INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL ONCOLYTIC VIRUS THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL ONCOLYTIC VIRUS THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL ONCOLYTIC VIRUS THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL PD-1 INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL PD-1 INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL PD-1 INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL PD-L1 INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL PD-L1 INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL PD-L1 INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL ADOPTIVE CELL TRANSFER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL ADOPTIVE CELL TRANSFER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL ADOPTIVE CELL TRANSFER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL CHECKPOINT INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL CHECKPOINT INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL CHECKPOINT INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL CYTOKINE THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL CYTOKINE THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL CYTOKINE THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL ONCOLYTIC VIRUS THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL ONCOLYTIC VIRUS THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL ONCOLYTIC VIRUS THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL VACCINE THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL VACCINE THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL VACCINE THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL FIRST LINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL FIRST LINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL FIRST LINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL FOURTH LINE AND BEYOND MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL FOURTH LINE AND BEYOND MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL FOURTH LINE AND BEYOND MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL SECOND LINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL SECOND LINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL SECOND LINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL THIRD LINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL THIRD LINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL THIRD LINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL INTRATUMORAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL INTRATUMORAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL INTRATUMORAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL INTRAVENOUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL INTRAVENOUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL INTRAVENOUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL SUBCUTANEOUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL SUBCUTANEOUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL SUBCUTANEOUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL HEMATOLOGIC MALIGNANCIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL HEMATOLOGIC MALIGNANCIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL HEMATOLOGIC MALIGNANCIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL LEUKEMIA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL LEUKEMIA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL LEUKEMIA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL LYMPHOMA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL LYMPHOMA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL LYMPHOMA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL MULTIPLE MYELOMA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL MULTIPLE MYELOMA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL MULTIPLE MYELOMA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL SOLID TUMORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL SOLID TUMORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL SOLID TUMORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL BREAST CANCER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL BREAST CANCER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL BREAST CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL COLORECTAL CANCER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL COLORECTAL CANCER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL COLORECTAL CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL LUNG CANCER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL LUNG CANCER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL LUNG CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL MELANOMA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL MELANOMA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL MELANOMA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. ASIA-PACIFIC CANCER IMMUNOTHERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 100. ASIA-PACIFIC CANCER IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 101. ASIA-PACIFIC CANCER IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 102. ASIA-PACIFIC CANCER IMMUNOTHERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 103. ASIA-PACIFIC CANCER IMMUNOTHERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 104. ASIA-PACIFIC CANCER IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 105. ASIA-PACIFIC CANCER IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 106. ASIA-PACIFIC CANCER IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 107. ASIA-PACIFIC CANCER IMMUNOTHERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 108. NORTH AMERICA CANCER IMMUNOTHERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 109. NORTH AMERICA CANCER IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 110. NORTH AMERICA CANCER IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 111. NORTH AMERICA CANCER IMMUNOTHERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 112. NORTH AMERICA CANCER IMMUNOTHERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 113. NORTH AMERICA CANCER IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 114. NORTH AMERICA CANCER IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 115. NORTH AMERICA CANCER IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 116. NORTH AMERICA CANCER IMMUNOTHERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 117. LATIN AMERICA CANCER IMMUNOTHERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 118. LATIN AMERICA CANCER IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 119. LATIN AMERICA CANCER IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 120. LATIN AMERICA CANCER IMMUNOTHERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 121. LATIN AMERICA CANCER IMMUNOTHERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 122. LATIN AMERICA CANCER IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 123. LATIN AMERICA CANCER IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 124. LATIN AMERICA CANCER IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 125. LATIN AMERICA CANCER IMMUNOTHERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPE CANCER IMMUNOTHERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPE CANCER IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPE CANCER IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPE CANCER IMMUNOTHERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPE CANCER IMMUNOTHERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPE CANCER IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPE CANCER IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE CANCER IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPE CANCER IMMUNOTHERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 135. MIDDLE EAST CANCER IMMUNOTHERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 136. MIDDLE EAST CANCER IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 137. MIDDLE EAST CANCER IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 138. MIDDLE EAST CANCER IMMUNOTHERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 139. MIDDLE EAST CANCER IMMUNOTHERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 140. MIDDLE EAST CANCER IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 141. MIDDLE EAST CANCER IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 142. MIDDLE EAST CANCER IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 143. MIDDLE EAST CANCER IMMUNOTHERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 144. AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 145. AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 146. AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 147. AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 148. AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 149. AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 150. AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 151. AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 152. AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 153. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 154. ASEAN CANCER IMMUNOTHERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 155. ASEAN CANCER IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 156. ASEAN CANCER IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 157. ASEAN CANCER IMMUNOTHERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 158. ASEAN CANCER IMMUNOTHERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 159. ASEAN CANCER IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 160. ASEAN CANCER IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 161. ASEAN CANCER IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 162. ASEAN CANCER IMMUNOTHERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 163. GCC CANCER IMMUNOTHERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 164. GCC CANCER IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 165. GCC CANCER IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 166. GCC CANCER IMMUNOTHERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 167. GCC CANCER IMMUNOTHERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 168. GCC CANCER IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 169. GCC CANCER IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 170. GCC CANCER IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 171. GCC CANCER IMMUNOTHERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPEAN UNION CANCER IMMUNOTHERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPEAN UNION CANCER IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 174. EUROPEAN UNION CANCER IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 175. EUROPEAN UNION CANCER IMMUNOTHERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 176. EUROPEAN UNION CANCER IMMUNOTHERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 177. EUROPEAN UNION CANCER IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 178. EUROPEAN UNION CANCER IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 179. EUROPEAN UNION CANCER IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 180. EUROPEAN UNION CANCER IMMUNOTHERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 181. BRICS CANCER IMMUNOTHERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 182. BRICS CANCER IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 183. BRICS CANCER IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 184. BRICS CANCER IMMUNOTHERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 185. BRICS CANCER IMMUNOTHERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 186. BRICS CANCER IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 187. BRICS CANCER IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 188. BRICS CANCER IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 189. BRICS CANCER IMMUNOTHERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 190. G7 CANCER IMMUNOTHERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 191. G7 CANCER IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 192. G7 CANCER IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 193. G7 CANCER IMMUNOTHERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 194. G7 CANCER IMMUNOTHERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 195. G7 CANCER IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 196. G7 CANCER IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 197. G7 CANCER IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 198. G7 CANCER IMMUNOTHERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 199. NATO CANCER IMMUNOTHERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 200. NATO CANCER IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 201. NATO CANCER IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 202. NATO CANCER IMMUNOTHERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 203. NATO CANCER IMMUNOTHERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 204. NATO CANCER IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 205. NATO CANCER IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 206. NATO CANCER IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 207. NATO CANCER IMMUNOTHERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 208. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 209. UNITED STATES CANCER IMMUNOTHERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 210. UNITED STATES CANCER IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 211. UNITED STATES CANCER IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 212. UNITED STATES CANCER IMMUNOTHERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 213. UNITED STATES CANCER IMMUNOTHERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 214. UNITED STATES CANCER IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 215. UNITED STATES CANCER IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 216. UNITED STATES CANCER IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 217. UNITED STATES CANCER IMMUNOTHERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 218. CANADA CANCER IMMUNOTHERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 219. CANADA CANCER IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 220. CANADA CANCER IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 221. CANADA CANCER IMMUNOTHERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 222. CANADA CANCER IMMUNOTHERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 223. CANADA CANCER IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 224. CANADA CANCER IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 225. CANADA CANCER IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 226. CANADA CANCER IMMUNOTHERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 227. MEXICO CANCER IMMUNOTHERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 228. MEXICO CANCER IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 229. MEXICO CANCER IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 230. MEXICO CANCER IMMUNOTHERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 231. MEXICO CANCER IMMUNOTHERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 232. MEXICO CANCER IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 233. MEXICO CANCER IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 234. MEXICO CANCER IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 235. MEXICO CANCER IMMUNOTHERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 236. BRAZIL CANCER IMMUNOTHERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 237. BRAZIL CANCER IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 238. BRAZIL CANCER IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 239. BRAZIL CANCER IMMUNOTHERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 240. BRAZIL CANCER IMMUNOTHERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 241. BRAZIL CANCER IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 242. BRAZIL CANCER IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 243. BRAZIL CANCER IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 244. BRAZIL CANCER IMMUNOTHERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 245. UNITED KINGDOM CANCER IMMUNOTHERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 246. UNITED KINGDOM CANCER IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 247. UNITED KINGDOM CANCER IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 248. UNITED KINGDOM CANCER IMMUNOTHERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 249. UNITED KINGDOM CANCER IMMUNOTHERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 250. UNITED KINGDOM CANCER IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 251. UNITED KINGDOM CANCER IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 252. UNITED KINGDOM CANCER IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 253. UNITED KINGDOM CANCER IMMUNOTHERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 254. GERMANY CANCER IMMUNOTHERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 255. GERMANY CANCER IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 256. GERMANY CANCER IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 257. GERMANY CANCER IMMUNOTHERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 258. GERMANY CANCER IMMUNOTHERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 259. GERMANY CANCER IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 260. GERMANY CANCER IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 261. GERMANY CANCER IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 262. GERMANY CANCER IMMUNOTHERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 263. FRANCE CANCER IMMUNOTHERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 264. FRANCE CANCER IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 265. FRANCE CANCER IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 266. FRANCE CANCER IMMUNOTHERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 267. FRANCE CANCER IMMUNOTHERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 268. FRANCE CANCER IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 269. FRANCE CANCER IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 270. FRANCE CANCER IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 271. FRANCE CANCER IMMUNOTHERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 272. RUSSIA CANCER IMMUNOTHERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 273. RUSSIA CANCER IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 274. RUSSIA CANCER IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 275. RUSSIA CANCER IMMUNOTHERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 276. RUSSIA CANCER IMMUNOTHERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 277. RUSSIA CANCER IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 278. RUSSIA CANCER IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 279. RUSSIA CANCER IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 280. RUSSIA CANCER IMMUNOTHERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 281. ITALY CANCER IMMUNOTHERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 282. ITALY CANCER IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 283. ITALY CANCER IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 284. ITALY CANCER IMMUNOTHERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 285. ITALY CANCER IMMUNOTHERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 286. ITALY CANCER IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 287. ITALY CANCER IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 288. ITALY CANCER IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 289. ITALY CANCER IMMUNOTHERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 290. SPAIN CANCER IMMUNOTHERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 291. SPAIN CANCER IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 292. SPAIN CANCER IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 293. SPAIN CANCER IMMUNOTHERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 294. SPAIN CANCER IMMUNOTHERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 295. SPAIN CANCER IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 296. SPAIN CANCER IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 297. SPAIN CANCER IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 298. SPAIN CANCER IMMUNOTHERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 299. CHINA CANCER IMMUNOTHERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 300. CHINA CANCER IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 301. CHINA CANCER IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 302. CHINA CANCER IMMUNOTHERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 303. CHINA CANCER IMMUNOTHERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 304. CHINA CANCER IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 305. CHINA CANCER IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 306. CHINA CANCER IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 307. CHINA CANCER IMMUNOTHERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 308. INDIA CANCER IMMUNOTHERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 309. INDIA CANCER IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 310. INDIA CANCER IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 311. INDIA CANCER IMMUNOTHERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 312. INDIA CANCER IMMUNOTHERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 313. INDIA CANCER IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 314. INDIA CANCER IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 315. INDIA CANCER IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 316. INDIA CANCER IMMUNOTHERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 317. JAPAN CANCER IMMUNOTHERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 318. JAPAN CANCER IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 319. JAPAN CANCER IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 320. JAPAN CANCER IMMUNOTHERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 321. JAPAN CANCER IMMUNOTHERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 322. JAPAN CANCER IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 323. JAPAN CANCER IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 324. JAPAN CANCER IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 325. JAPAN CANCER IMMUNOTHERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 326. AUSTRALIA CANCER IMMUNOTHERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 327. AUSTRALIA CANCER IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 328. AUSTRALIA CANCER IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 329. AUSTRALIA CANCER IMMUNOTHERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 330. AUSTRALIA CANCER IMMUNOTHERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 331. AUSTRALIA CANCER IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 332. AUSTRALIA CANCER IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 333. AUSTRALIA CANCER IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 334. AUSTRALIA CANCER IMMUNOTHERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 335. SOUTH KOREA CANCER IMMUNOTHERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 336. SOUTH KOREA CANCER IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 337. SOUTH KOREA CANCER IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 338. SOUTH KOREA CANCER IMMUNOTHERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 339. SOUTH KOREA CANCER IMMUNOTHERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 340. SOUTH KOREA CANCER IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 341. SOUTH KOREA CANCER IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 342. SOUTH KOREA CANCER IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 343. SOUTH KOREA CANCER IMMUNOTHERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)